Professional Documents
Culture Documents
Berende Ab Ci
Berende Ab Ci
Berende Ab Ci
Conclusions
A 2-week treatment with ceftriaxone followed by a 12-week regimen of doxycycline or
clarithromycin/hydroxychloroquine did not lead to better cognitive performance compared to
a 2-week regimen of ceftriaxone in patients with Lyme disease–attributed persistent symptoms.
ClinicalTrials.gov identifier
NCT01207739.
Classification of evidence
This study provides Class II evidence that longer-term antibiotics in patients with borreliosis-
attributed persistent symptoms does not increase cognitive performance compared to shorter-
term antibiotics.
From the Department of Medicine (A.B., H.J.M.t.H., F.J.V., B.J.K.), Radboud Center for Infectious Diseases (A.B., H.J.M.t.H., F.J.V., B.J.K.), and Department of Medical Psychology (M.L.V.,
H.v.M., A.W.M.E., R.P.C.K.), Radboud University Medical Center; Department of Medicine (F.J.V.), Sint Maartenskliniek, Nijmegen; Institute of Psychology (H.v.M., A.W.M.E.), Health,
Medical, and Neuropsychology Unit, Leiden University; and Donders Institute for Brain, Cognition and Behaviour (R.P.C.K.), Radboud University, Nijmegen, the Netherlands.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. e1447
Glossary
EOT = end of treatment; Ig = immunoglobulin; PLEASE = Persistent Lyme Empiric Antibiotic Study Europe.
Many patients who experience persistent symptoms that are Standard protocol approvals, registrations,
attributed to Lyme borreliosis complain of cognitive problems and patient consents
such as memory loss, word-finding difficulties, and concen- The local ethics committee has approved the PLEASE
tration problems.1,2 However, previous studies have failed to protocol (CMO region Arnhem-Nijmegen, 2009/187,
show significant correlations between subjective memory NL27344.091.09). All participants provided written informed
complaints and objective test performances in patients with consent. The trial was registered with ClinicalTrials.gov
Lyme borreliosis and other patients.3–6 This makes assessing (NCT01207739).
neurocognitive function with objective neuropsychological
tests important. Randomization and masking
Computerized randomization distributed patients into 3 groups
Several small studies have investigated the neurocognitive in a 1:1:1 ratio. The randomization was balanced by mini-
performance of patients with Lyme disease compared to healthy mization for duration of symptoms (<1 or ≥1 year), age (<40
participants. Most found a worse performance in the patient or ≥40 years), sex, and baseline RAND-36 Health Status In-
group.6–13 Deficits observed in patients with persistent symp- ventory Global Health Composite score.23 An independent
toms attributed to Lyme disease are best typified as a combi- web manager entered the randomization list, consisting of
nation of reduced processing speed and memory problems.9 consecutive medication numbers, into a secured web-based
database. None of the participants or personnel involved in
To date, it is unknown whether the cognitive problems reported the trial (apart from the web manager and study pharmacist)
by patients with persistent Lyme disease–attributed symptoms were aware of the assignments to study groups.
are due to an insufficiently treated low-grade Borrelia burgdorferi
infection, remnants of past infection, or incorrect attribution Classification of evidence
to Lyme borreliosis. Although most guidelines recommend The primary research question is whether longer-term anti-
antimicrobial therapy for a maximum of 2 to 4 weeks,14,15 others biotic treatment with 2 weeks of ceftriaxone followed by 12
recommend longer-term antibiotic treatment.16 weeks of doxycycline or clarithromycin/hydroxychloroquine
improves cognitive performance in patients with persistent
Previous studies have not been conclusive in proving the effects symptoms attributed to Lyme borreliosis compared to shorter-
of longer-term antibiotic therapy on cognition.5,17–20 Further- term antibiotic treatment with 2 weeks of ceftriaxone. This trial
more, the trials performed were small (n = 129 and n = 37).5,17 provides Class II evidence that longer-term treatment does not
The present study, the largest to date, was performed to eval- lead to additional improvement.
uate the effect of prolonged antimicrobial treatment compared
to shorter-term treatment on neurocognitive function in Intervention
patients with symptoms attributed to Lyme borreliosis. All patients were treated with open-label intravenous cef-
triaxone daily for 2 weeks. After completion, patients started
on a blinded and randomized 12-week oral regimen of doxy-
Methods cycline, clarithromycin-hydroxychloroquine, or placebo. The
study drugs and placebo had an identical appearance. More
Study design and participants details on the intervention have been provided in the study
The data for this neurocognitive study were collected as sec- protocol of the PLEASE trial.21
ondary outcomes of the Persistent Lyme Empiric Antibiotic
Study Europe (PLEASE), a multicenter, placebo-controlled, Procedures
double-blind randomized clinical trial that was performed Cognitive performance was assessed at baseline, after end of
in the Netherlands at 2 locations (Sint Maartenskliniek and treatment (EOT) at 14 weeks, at 26 weeks, and at 40 weeks
Radboud University Medical Center). From October 2010 with an extensive neuropsychological test battery covering
through June 2013, patients were enrolled in this trial. The the 5 major cognitive domains: episodic memory, attention/
study design and protocol, inclusion and exclusion criteria,21 working memory, fluency, speed of information processing,
and main outcomes were previously published.22 Patients and executive function. We measured episodic memory with
with ongoing symptoms such as musculoskeletal pain, neu- the Rey Auditory Verbal Learning Test, attention/working
ralgia, sensory disturbances, or cognitive complaints were memory with the Digit Span Test, language with the Category
included if they also had B burgdorferi immunoglobulin (Ig) Fluency Test, and speed of information processing with the
G or IgM antibodies or if the complaints were temporally Trail Making Test Part A, the average speed of cards I and
linked to an erythema migrans or otherwise proven symp- II from the Stroop Color-Word Test, and the Symbol-Digit
tomatic Lyme borreliosis. Substitution Test. We assessed executive function with the
Trail Making Test Interference Score (Part B/Part A) and study sample. The compound score for each cognitive domain
the Stroop Interference Score (card III/average of cards was obtained by calculating the mean of the z scores for tests
I and II). The raw test scores were standardized into z scores making up that domain. Higher scores represent better per-
by use of the pooled mean of baseline scores of the entire formance. Further details on the neuropsychological assessment
b
Current symptoms, n (%)
Duration of symptoms, median (IQR), y 2.7 (1.3–7.6) 2.8 (1.4–5.5) 2.3 (0.9–6.2)
f
Education level, n (%)
b
Employment, n (%)
g
Cognitive domain compound score, mean (95% CI)
Episodic memory −0.08 (−0.29 to 0.12) 0.06 (−0.12 to 0.24) 0.19 (0.02 to 0.37)
Attention/working memory −0.11 (−0.35 to 0.13) 0.26 (0.06 to 0.46) 0.06 (−0.17 to 0.29)
Verbal fluency −0.09 (−0.31 to 0.13) −0.01 (−0.22 to 0.20) 0.18 (−0.06 to 0.41)
Speed of information processing 0.00 (−0.20 to 0.19) 0.12 (−0.04 to 0.28) 0.10 (−0.08 to 0.27)
Executive function −0.02 (−0.21 to 0.17) 0.04 (−0.14 to 0.23) 0.11 (−0.06 to 0.27)
Mean z score (95% CI) 0.19 (0.03 to 0.35) 0.27 (0.13 to 0.41) 0.27 (0.12 to 0.42)
Difference with placebo (95% CI) −0.08 (−0.34 to 0.18) 0.00 (−0.25 to 0.25) —
Mean z score (95% CI) 0.21 (0.05 to 0.37) 0.16 (0.01 to 0.30) 0.25 (0.10 to 0.40)
Difference with placebo (95% CI) −0.04 (−0.30 to 0.22) −0.10 (−0.35 to 0.16) —
Mean z score (95% CI) 0.18 (0.02 to 0.35) 0.24 (0.09 to 0.39) 0.13 (−0.03 to 0.28)
Difference with placebo (95% CI) 0.06 (−0.22 to 0.34) 0.11 (−0.16 to 0.38) —
Mean z score (95% CI) 0.25 (0.15 to 0.36) 0.30 (0.21 to 0.39) 0.34 (0.24 to 0.44)
Difference with placebo (95% CI) −0.09 (−0.26 to 0.09) −0.04 (−0.20 to 0.13) —
Mean z score (95% CI) 0.14 (−0.01 to 0.28) 0.13 (0.00 to 0.27) 0.19 (0.05 to 0.32)
Difference with placebo (95% CI) −0.05 (−0.30 to 0.19) −0.05 (−0.29 to 0.18) —
Figure 2 Mean z score (95% confidence interval) per treatment group per neuropsychological domain at all study visits
(A) Episodic memory, (B) working memory, (C) fluency, (D) speed of information processing, and (E) executive function.
Episodic memory
Ceftriaxone + doxycycline 0.16 (0.08) 0.056 0.26 (0.07) <0.01 0.20 (0.08) 0.015
Ceftriaxone + clarithromycin 0.22 (0.08) <0.01 0.27 (0.07) <0.01 0.18 (0.07) 0.017
Ceftriaxone + placebo 0.19 (0.07) <0.01 0.14 (0.08) 0.090 0.19 (0.08) 0.013
Attention/working memory
Ceftriaxone + doxycycline 0.18 (0.08) 0.031 0.26 (0.07) <0.01 0.32 (0.10) <0.01
Ceftriaxone + clarithromycin 0.04 (0.08) 0.589 0.11 (0.07) 0.132 0.23 (0.09) 0.015
Ceftriaxone + placebo 0.19 (0.07) 0.012 0.29 (0.09) <0.01 0.37 (0.09) <0.01
Verbal fluency
Ceftriaxone + doxycycline 0.19 (0.09) 0.033 0.32 (0.08) <0.01 0.29 (0.09) <0.01
Ceftriaxone + clarithromycin 0.20 (0.09) 0.025 0.39 (0.09) <0.01 0.46 (0.11) <0.01
Ceftriaxone + placebo 0.09 (0.08) 0.245 0.12 (0.10) 0.209 0.35 (0.09) <0.01
Ceftriaxone + doxycycline 0.19 (0.05) <0.01 0.33 (0.05) <0.01 0.46 (0.06) <0.01
Ceftriaxone + clarithromycin 0.22 (0.05) <0.01 0.41 (0.06) <0.01 0.50 (0.07) <0.01
Ceftriaxone + placebo 0.26 (0.05) <0.01 0.40 (0.06) <0.01 0.47 (0.07) <0.01
Executive function
Ceftriaxone + doxycycline 0.11 (0.07) 0.1290 0.22 (0.08) 0.010 0.17 (0.09) 0.075
Ceftriaxone + clarithromycin 0.10 (0.08) 0.1884 0.20 (0.10) 0.044 0.20 (0.09) 0.031
Ceftriaxone + placebo 0.11 (0.09) 0.2013 0.10 (0.08) 0.185 0.17 (0.07) 0.019
a
Bonferroni correction was applied, i.e., α was adjusted to 0.01.
report subjective cognitive complaints at baseline (n = 32) Previous case series have suggested a significant cognitive im-
did not yield different results, nor did post hoc analyses on provement on most domains after antibiotic treatment.18,19
the subgroup of patients with severe subjective symptoms as Two randomized controlled treatment trials have also demon-
measured by the Cognitive Failures Questionnaire.29 With strated significant improvement of objective test scores after
a cutoff value for the Cognitive Failures Questionnaire set at 44, treatment compared to baseline performance.5,17 However, no
111 patients were considered to have severe neurocognitive significant differences were found between those receiving
symptoms. Finally, subgroup analyses including only patients antibiotics and those receiving placebo in 1 trial,5 and the other
who had a high burden of symptoms (i.e., those who were on trial did not show sustainable effects of antibiotic treatment on
sick leave or disability support, n = 81) also did not show cognition.17 In our trial, mixed-model analyses showed no dif-
a significant difference between placebo and antimicrobial ference over time. Cognitive improvements were found at weeks
treatment groups. Using analysis of covariance, with sick leave/ 14, 26, and 40 only when the separate domains were directly
disability and baseline cognitive function as covariates, we compared with baseline, and changes over time were at most in
found no significant difference between treatment groups. the small to moderate range. Because an improvement was seen
in all treatment groups, including the placebo control group, the
observed changes appear to be neither clinically relevant nor
treatment specific. The global difference found over time may be
Discussion the result of a placebo effect, nonspecific practice effects,
This study showed that prolonged antibiotic treatment for 3 spontaneous improvement over time, or a combination of these.
months in patients with persistent Lyme borreliosis–attributed
symptoms does not have an additional beneficial effect on The present study is the largest trial performed to date. It was
cognitive performance compared to short-term treatment. specifically designed prospectively to study treatment outcomes,